Skip to main content
. 2014 Apr 21;6(11):8401–8406. doi: 10.1021/am501309d

Figure 1.

Figure 1

Immunofluorescence image of VEGF in DC-ECM after treatment first with VEGF pAb followed by FITC-labeled goat antirabbit IgG antibody (a) and its control only treated with FITC-labeled goat antirabbit IgG antibody (b), and a DAPI fluorescence image of the coumarin-triazole in DC-ECM-HPG after CuAAC reaction with the coumarin-azide 1 (c), and its control as DC-ECM after CuAAC reaction with the coumarin-azide 1 (d).